scholarly journals Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life

2010 ◽  
Vol 22 (4) ◽  
pp. 389 ◽  
Author(s):  
Young Wook Lee ◽  
Eun Joo Park ◽  
In Ho Kwon ◽  
Kwang Ho Kim ◽  
Kwang Joong Kim
Keyword(s):  
Quality Of Life ◽  
Clinical Response ◽  
Response To Therapy ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis

Dermatology ◽  
2008 ◽  
Vol 216 (3) ◽  
pp. 260-270 ◽  
Author(s):  
Dennis A. Revicki ◽  
Mary K. Willian ◽  
Alan Menter ◽  
Jean-Hilaire Saurat ◽  
Neesha Harnam ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Response ◽  
Plaque Psoriasis ◽  
Response To Therapy ◽  
Health Related Quality ◽  
Life Outcomes ◽  
Severe Plaque Psoriasis ◽  
Related Quality ◽  
Health Related

The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4558-4558 ◽  
Author(s):  
L. Kvols ◽  
J. E. Glusman ◽  
E. A. Hahn ◽  
E. Wang ◽  
K. Öberg ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Response ◽  
Functional Assessment ◽  
Well Being ◽  
Health Related Quality ◽  
Metastatic Carcinoid ◽  
Octreotide Lar ◽  
Related Quality ◽  
Health Related

4558 Background: Pasireotide is a novel multi-ligand somatostatin analogue with high affinity binding for four of the five somatostatin receptor subtypes (sst1,2,3 and sst5). This Phase II clinical trial showed that pasireotide is effective in controlling the symptoms of diarrhea and flushing in 27% of patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. The impact of pasireotide therapy on health-related quality of life (HRQL) was also evaluated. Methods: Patients in this open-label, multicenter study initially received pasireotide 300 μg sc bid which was escalated to a maximum dose of 1,200 μg sc bid until clinical response was achieved. Data are reported for the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D) instrument. FACIT-D comprises the Functional Assessment of Cancer Therapy-General (FACT-G) score, which measures physical, social, emotional and functional well-being, plus a symptom-specific sub-scale which measures HRQL specific to diarrhea. FACIT-D baseline assessment was obtained on day 1 immediately before dosing, and then monthly thereafter. FACIT-D sub-scale and total scores at baseline and after 1, 2, and 3 months of pasireotide treatment are described by categories of clinical response. Results: 45 patients (mean age 61 years; range 40–83) received treatment, and 44 were eligible for the efficacy and HRQL analyses. Functional well-being scores, symptom-specific scores and total FACIT-D scores of non-responders tended to be lower at baseline and during treatment than those of responders. The three sub-scale and summary FACIT-D scores exhibited relatively stable mean HRQL scores and similar patterns of variability in clinical responders and non- responders through the third month of pasireotide treatment. Conclusions: HRQL was stable during treatment with pasireotide in patients with advanced metastatic disease refractory or resistant to octreotide LAR. Additional work in HRQL study design and evaluation of HRQL endpoints in patients with carcinoid disease is indicated, and will further improve our understanding of quality of life in patients with this disease. [Table: see text]

scholarly journals Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3500-3500
Author(s):  
Pratibha Bhatia ◽  
Sumeet Prakash Mirgh ◽  
Vishvdeep Khushoo ◽  
Faran Naim ◽  
Ambar Garg ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Response Rates ◽  
Response To Therapy ◽  
Clinical Depression ◽  
Molecular Response ◽  
Health Related Quality ◽  
First Line ◽  
Related Quality ◽  
Health Related

Introduction: Clinical Depression experienced in Chronic Myeloid Leukemia (CML) is common, with a prevalence of 15- 30%. Compliance to TKI therapy in CML is a crucial factor. However, the lifelong duration of treatment impacts overall health related Quality of Life (QoL) in CML. In the absence of TKI resistance and depression, there is a better prognosis of patients conferring a better QoL and response to therapy. Methods: 98 patients on first line Imatinib (n=81) and Nilotinib (n=17) with a minimum TKI duration of 6 months were prospectively recruited, including their data on baseline Sokal, Eutos and Hasford Scores. Measures of Depression, QoL and Adherence were evaluated using Patient Health Questionnaire 9 item (PHQ-9), Survey Form - Health Related Quality of Life 36 item (SF-36) and Medication Adherence Rating Scale (MARS), respectively. Correlation of Depressive scores with QoL and Adherence were analysed. Similarly, all three variables were studied for their impact on treatment response (assessed by RQ-PCR-BCR ABL). Results: Frequency of Depression reported in CML patients was no (n=4), minimal (n=22), mild (n=47), moderate (n=19), moderately-severe (n=5), severe depression (n=1). Adherence was found to be 86%. In our study, majority of our Depressive Scores negatively correlated with QoL domains and Adherence using Pearson Correlation co-efficient (p value<0.05).Similarly, severity of depression was found to be significantly associated with QoL domains using one way ANCOVA, where age was adjusted as covariate. Similarly, on evaluating treatment outcomes using SPSSv.23 in 94 patients, it was found that, there was a positive trend of Depression, QoL, and Adherence with response to therapy. Amongst 94 patients who responded to treatment, 8.5% (n=8) patients were found to be in Complete Cytogenetic Response (CCyR), 59.5% (n=56) patients were in Major Molecular Response (MMR), and 31.9% (n=30) patients were in Deep Molecular Response (MR4) with first line TKIs. Most frequent side effects seen with TKIs were hypopigmentation (94.8%;n=93), weight gain (40.8%;n=40), vomiting (17.34%;n=17), QT prolongation (12.24%;n=12), myalgia (5.1%;n=5), facial puffiness (9.47%;n=9), giddiness (7.1;n=7), leg aches (11.22%;n=11) and nausea (9.1%;n=9). Our study limitations were that a minority of patients who discontinued therapy on long term follow-up owing to personal reasons, may report more clinical depression and worsened QoL which could thereby impact response. Additionally, we only assessed impact on response rates with first line TKIs. Conclusion: Clinical depression exists in CML which negatively impact QoL and compliance. To conclude, lesser depressive state leads to improved QoL and more adherence, which indirectly produces better response rates to TKI therapy. This could pave the way for screening patients on TKIs for early diagnosis of depression, and its impact on QoL before and after intervention with behavioural or pharmacological therapy. Disclosures No relevant conflicts of interest to declare.

Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B

2012 ◽  
Vol 10 (3) ◽  
pp. 291-296 ◽  
Author(s):  
Jeong Han Kim ◽  
So Young Kwon ◽  
Young Sok Lee ◽  
Joon Hyoek Lee ◽  
Yil–Seob Lee ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virologic Response ◽  
Response To Therapy ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus

2021 ◽  
Vol 8 ◽  
Author(s):  
Alvaro Gomez ◽  
Victor Qiu ◽  
Arvid Cederlund ◽  
Alexander Borg ◽  
Julius Lindblom ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Response ◽  
Physical Functioning ◽  
Standard Therapy ◽  
Organ Damage ◽  
Health Related Quality ◽  
Sf 36 ◽  
Related Quality ◽  
Health Related

Objective: To determine the prevalence of adverse health-related quality of life (HRQoL) outcomes in patients with SLE who achieved an adequate clinical response after a 52-week long standard therapy plus belimumab or placebo, and identify contributing factors.Methods: We included patients who met the primary endpoint of the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials, i.e., SLE Responder Index 4 (total population: N = 760/1,684; placebo: N = 217/562; belimumab 1 mg/kg: N = 258/559; belimumab 10 mg/kg: N = 285/563). Adverse HRQoL outcomes were defined as SF-36 scale scores ≤ the 5th percentile derived from age- and sex-matched population-based norms, and FACIT-Fatigue scores <30. We investigated factors associated with adverse HRQoL outcomes using logistic regression analysis.Results: We found clinically important diminutions of HRQoL in SLE patients compared with matched norms and high frequencies of adverse HRQoL outcomes, the highest in SF-36 general health (29.1%), followed by FACIT-Fatigue (25.8%) and SF-36 physical functioning (25.4%). Overall, frequencies were higher with increasing age. Black/African American and White/Caucasian patients reported higher frequencies than Asians and Indigenous Americans, while Hispanics experienced adverse HRQoL outcome less frequently than non-Hispanics. Established organ damage was associated with adverse physical but not mental HRQoL outcomes; particularly, damage in the cardiovascular (OR: 2.12; 95% CI: 1.07–4.21; P = 0.032) and musculoskeletal (OR: 1.41; 95% CI: 1.01–1.96; P = 0.041) domains was associated with adverse SF-36 physical component summary. Disease activity showed no impact on HRQoL outcomes. In multivariable logistic regression analysis, addition of belimumab to standard therapy was associated with lower frequencies of adverse SF-36 physical functioning (OR: 0.59; 95% CI: 0.39–0.91; P = 0.016) and FACIT-F (OR: 0.53; 95% CI: 0.34–0.81; P = 0.004).Conclusions: Despite adequate clinical response to standard therapy plus belimumab or placebo, a substantial proportion of SLE patients still reported adverse HRQoL outcomes. While no impact was documented for disease activity, established organ damage contributed to adverse outcome within physical HRQoL aspects and add-on belimumab was shown to be protective against adverse physical functioning and severe fatigue.

scholarly journals Achieving clinical response in postpartum depression leads to improvement in health-related quality of life

2021 ◽  
pp. 1-11
Author(s):  
Margaret E. Gerbasi ◽  
Mark Kosinski ◽  
Samantha Meltzer-Brody ◽  
Sarah Acaster ◽  
Moshe Fridman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Postpartum Depression ◽  
Clinical Response ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related
Sign in / Sign up

Export Citation Format

Share Document